Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Regulus Therapeutics Inc’s stock clocked out at $1.60, down -5.04% from its previous closing price of $1.68. In other words, the price has decreased by -$5.04 from its previous closing price. On the day, 0.67 million shares were traded. RGLS stock price reached its highest trading level at $1.77 during the session, while it also had its lowest trading level at $1.55.
Ratios:
To gain a deeper understanding of RGLS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.52 and its Current Ratio is at 10.52. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 27, 2025, Upgraded its rating to Overweight and sets its target price to $6 from $3 previously.
On August 02, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.
On March 18, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $6.Leerink Partners initiated its Outperform rating on March 18, 2024, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 30 ’25 when Hagan Joseph P bought 50,000 shares for $1.09 per share. The transaction valued at 54,260 led to the insider holds 260,808 shares of the business.
BALTIMORE DAVID bought 19,610 shares of RGLS for $20,787 on Jan 30 ’25. The Director now owns 22,169 shares after completing the transaction at $1.06 per share. On Jan 13 ’25, another insider, Aker Christopher Ray, who serves as the Sr. VP & General Counsel of the company, sold 38,547 shares for $1.26 each. As a result, the insider received 48,693 and left with 54,634 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGLS now has a Market Capitalization of 112322072 and an Enterprise Value of 36903104.
Stock Price History:
The Beta on a monthly basis for RGLS is 1.00, which has changed by -0.4074074 over the last 52 weeks, in comparison to a change of -0.028342128 over the same period for the S&P500. Over the past 52 weeks, RGLS has reached a high of $2.90, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 18.40%, while the 200-Day Moving Average is calculated to be 4.16%.
Shares Statistics:
It appears that RGLS traded 1.12M shares on average per day over the past three months and 4367040 shares per day over the past ten days. A total of 65.50M shares are outstanding, with a floating share count of 53.18M. Insiders hold about 19.71% of the company’s shares, while institutions hold 63.67% stake in the company. Shares short for RGLS as of 1741910400 were 2037305 with a Short Ratio of 1.81, compared to 1739491200 on 2029271. Therefore, it implies a Short% of Shares Outstanding of 2037305 and a Short% of Float of 3.9.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
